KeraLink International, a nonprofit organization dedicated to eradicating corneal blindness globally, has an ambitious goal: ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Traumatic corneal abrasions are relatively common and there is a lack of consensus about analgesia in their management. It is therefore important to document the clinical efficacy and safety profile ...

References: Krystal Biotech announces first patient dosed in phase 3 clinical trial of KB803 for the treatment and prevention of corneal abrasions in patients with dystrophic epidermolysis bullosa.

IOLITE Phase 3 Study IOLITE is an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 study with a crossover design to evaluate KB803, administered as an eye drop, for the treatment ...

This defined population was followed prospectively for 12 months by 15 VHWs who were trained to identify post-traumatic corneal abrasions with fluorescein dye and a blue torch and to administer 1% ...

This article will discuss the underlying pathological mechanisms and the clinical features of corneal involvement in allergic eye disease and outline current and new options for treatment.

Keratectomy Surgical removal of corneal plaques is recommended to alleviate severe symptoms and to allow for corneal re-epithelization.

IOLITE is an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 study with a crossover design to evaluate KB803, administered as an eye drop, for the treatment and prevention of ...